{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:12:45Z","timestamp":1789841565811,"version":"4.0.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T00:00:00Z","timestamp":1503964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1038\/bjc.2017.290","type":"journal-article","created":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T20:02:11Z","timestamp":1504036931000},"page":"1278-1285","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Dovitinib in patients with gastrointestinal stromal tumour refractory and\/or intolerant to imatinib"],"prefix":"10.1038","volume":"117","author":[{"given":"Heikki","family":"Joensuu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Comandone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Martin-Broto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Fumagalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Grignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier Garcia","family":"Del Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Adenis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Valverde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Lopez","family":"Pousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bouch\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Italiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Crippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Camozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Castellana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Le Cesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,29]]},"reference":[{"key":"BFbjc2017290_CR1","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1093\/annonc\/mdu237","volume":"25","author":"A Adenis","year":"2014","unstructured":"Adenis A, Blay JY, Bui-Nguyen B, Bouche O, Bertucci F, Isambert N, Bompas E, Chaigneau L, Domont J, Ray-Coquard I, Bl\u00e9sius A, Van Tine BA, Bulusu VR, Dubreuil P, Mansfield CD, Acin Y, Moussy A, Hermine O, Le Cesne A (2014) Masitinib in advanced gastrointestinal stromal tumour (GIST) after failure of imatinib: a randomized controlled open-label study. Ann Oncol 25: 1762\u20131769.","journal-title":"Ann Oncol"},{"key":"BFbjc2017290_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/01.pas.0000213307.05811.f0","volume":"31","author":"A Agaimy","year":"2007","unstructured":"Agaimy A, Wunsch PH, Hofstaedter F, Blaszyk H, Rummele P, Gaumann A, Dietmaier W, Hartmann A (2007) Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 31: 113\u2013120.","journal-title":"Am J Surg Pathol"},{"key":"BFbjc2017290_CR3","doi-asserted-by":"publisher","first-page":"4182","DOI":"10.1158\/1078-0432.CCR-04-2245","volume":"11","author":"CR Antonescu","year":"2005","unstructured":"Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, Leversha MA, Jeffrey PD, Desantis D, Singer S, Brennan MF, Maki RG, DeMatteo RP (2005) Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11: 4182\u20134190.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2017290_CR4","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1158\/1055-9965.EPI-08-0237","volume":"17","author":"A Artinyan","year":"2008","unstructured":"Artinyan A, Kim J, Soriano P, Chow W, Bhatia S, Ellenhorn JD (2008) Metastatic gastrointestinal stromal tumors in the era of imatinib: improved survival and elimination of socioeconomic survival disparities. Cancer Epidemiol Biomarkers Prev 17: 2194\u20132201.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"BFbjc2017290_CR5","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s40265-015-0440-8","volume":"75","author":"S Bauer","year":"2015","unstructured":"Bauer S, Joensuu H (2015) Emerging agents for the treatment of advanced, imatinib resistant gastrointestinal stromal tumors: current status and future directions. Drugs 75: 1323\u20131324.","journal-title":"Drugs"},{"key":"BFbjc2017290_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00280-010-1431-9","volume":"68","author":"RS Benjamin","year":"2011","unstructured":"Benjamin RS, Sch\u00f6ffski P, Hartmann JT, Van Oosterom A, Bui BN, Duyster J, Schuetze S, Blay JY, Reichardt P, Rosen LS, Skubitz K, McCoy S, Sun YN, Stepan DE, Baker L (2011) Efficacy and safety of motesanib, an oral inhibitor of VEGF,PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors. Cancer Chemother Pharmacol 68: 69\u201377.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFbjc2017290_CR7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1159\/000355898","volume":"41","author":"PG Casali","year":"2014","unstructured":"Casali PG (2014) Success and limitation of targeted cancer therapy in gastrointestinal stromal tumors. Prog Tumor Res 41: 51\u201361.","journal-title":"Prog Tumor Res"},{"key":"BFbjc2017290_CR8","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s00280-011-1785-7","volume":"69","author":"C Cauchi","year":"2012","unstructured":"Cauchi C, Somaiah N, Engstrom PF, Litwin S, Lopez M, Lee J, Davey M, Bove B, von Mehren M (2012) Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib. Cancer Chemother Pharmacol 69: 977\u2013982.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFbjc2017290_CR9","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/nrc3143","volume":"11","author":"CL Corless","year":"2011","unstructured":"Corless CL, Barnett CM, Heinrich MC (2011) Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer 11: 865\u2013878.","journal-title":"Nat Rev Cancer"},{"key":"BFbjc2017290_CR10","first-page":"3034","volume":"8","author":"R Dagher","year":"2002","unstructured":"Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, Rahman A, Chen G, Staten A, Griebel D, Pazdur R (2002) Approval summary: imatinib mesylate in the treatment of metastatic and\/or unrespectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8: 3034\u20133048.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2017290_CR11","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.ejca.2006.01.030","volume":"42","author":"M Debiec-Rychter","year":"2006","unstructured":"Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, Blay JY, Leyvraz S, Stul M, Casali PG, Zalcberg J, Verweij J, Van Glabbeke M, Hagemeijer A, Judson I EORTC Soft Tissue and Bone Sarcoma Group; Italian Sarcoma Group; Australasian GastroIntestinal Trials Group (2006) KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42: 1093\u20131103.","journal-title":"Eur J Cancer"},{"key":"BFbjc2017290_CR12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","volume":"381","author":"G Demetri","year":"2013","unstructured":"Demetri G, Reichardt P, Kang Y, Blay J-Y, Rutkowski P, Gelderbloom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Sch\u00f6ffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG GRID Study Investigators (2013) Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib (GRID): an international multicentre, randomized placebo-controlled, phase 3 trial. Lancet 381: 295\u2013302.","journal-title":"Lancet"},{"key":"BFbjc2017290_CR13","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","volume":"368","author":"GD Demetri","year":"2006","unstructured":"Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: a randomised controlled trial. Lancet 368: 1329\u20131338.","journal-title":"Lancet"},{"key":"BFbjc2017290_CR14","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1093\/annonc\/mdt484","volume":"25","author":"KN Ganjoo","year":"2014","unstructured":"Ganjoo KN, Villalobos VM, Kamaya A, Fisher GA, Butrynski JE, Morgan JA, Morgan JA, Wagner AJ, D\u2019Adamo D, McMillan A, Demetri GD, George S (2014) A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib. Ann Oncol 25: 236\u2013240.","journal-title":"Ann Oncol"},{"key":"BFbjc2017290_CR15","doi-asserted-by":"publisher","first-page":"7510","DOI":"10.1158\/1078-0432.CCR-09-0190","volume":"15","author":"AW Gramza","year":"2009","unstructured":"Gramza AW, Corless CL, Heinrich MC (2009) Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors. Clin Cancer Res 15: 7510\u20137518.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2017290_CR16","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.1200\/JCO.2006.06.2265","volume":"24","author":"MC Heinrich","year":"2006","unstructured":"Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M, Fletcher CD, Sandau K, McDougall K, Ou WB, Chen CJ, Fletcher JA (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24: 4764\u20134774.","journal-title":"J Clin Oncol"},{"key":"BFbjc2017290_CR17","doi-asserted-by":"publisher","first-page":"5352","DOI":"10.1200\/JCO.2007.15.7461","volume":"26","author":"MC Heinrich","year":"2008","unstructured":"Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, Town A, McKinley A, Ou WB, Fletcher JA, Fletcher CD, Huang X, Cohen DP, Baum CM, Demetri GD (2008) Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 26: 5352\u20135359.","journal-title":"J Clin Oncol"},{"key":"BFbjc2017290_CR18","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1158\/1535-7163.MCT-12-0223","volume":"11","author":"MC Heinrich","year":"2012","unstructured":"Heinrich MC, Marino-Enriquez A, Presnell A, Donsky RS, Griffith DJ, McKinley A, Patterson J, Taguchi T, Liang CW, Fletcher JA (2012) Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors. Mol Cancer Ther 11: 1770\u20131780.","journal-title":"Mol Cancer Ther"},{"key":"BFbjc2017290_CR19","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/bjc.2011.151","volume":"104","author":"H Joensuu","year":"2011","unstructured":"Joensuu H, De Braud F, Grignagni G, De Pas T, Spitalieri G, Coco P, Spreafico C, Boselli S, Toffalorio F, Bono P, Jalava T, Kappeler C, Aglietta M, Laurent D, Casali PG (2011) Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. Br J Cancer 104: 1686\u20131690.","journal-title":"Br J Cancer"},{"key":"BFbjc2017290_CR20","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S0140-6736(13)60106-3","volume":"382","author":"H Joensuu","year":"2013","unstructured":"Joensuu H, Hohenberger P, Corless CL (2013) Gastrointestinal stromal tumour. Lancet 382: 973\u2013983.","journal-title":"Lancet"},{"key":"BFbjc2017290_CR21","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1038\/bjc.2013.594","volume":"109","author":"YK Kang","year":"2013","unstructured":"Kang YK, Yoo C, Ryoo BY, Lee JJ, Tan E, Park I, Park JH, Choi YJ, Jo J, Ryu JS, Ryu MH (2013) Phase II study of dovitinib in patients with metastatic and\/or unresectable gastrointestinal stromal tumors after failure of imatinib and sunitinib. Br J Cancer 109: 2309\u20132315.","journal-title":"Br J Cancer"},{"key":"BFbjc2017290_CR22","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.5858\/2006-130-1466-GSTROM","volume":"130","author":"M Miettinen","year":"2006","unstructured":"Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 130: 1466\u20131478.","journal-title":"Arch Pathol Lab Med"},{"key":"BFbjc2017290_CR23","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.ejca.2012.10.009","volume":"49","author":"M Montemurro","year":"2013","unstructured":"Montemurro M, Gelderblom H, Bitz U, Schutte J, Blay JY, Joensuu H, Trent J, Bauer S, Rutkowski P, Duffaud F, Pink D (2013) Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: a retrospective analysis. Eur J Cancer 49: 1027\u20131031.","journal-title":"Eur J Cancer"},{"key":"BFbjc2017290_CR24","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/j.humpath.2011.01.024","volume":"42","author":"S Muenst","year":"2011","unstructured":"Muenst S, Thies S, Went P, Tornillo L, Bihl MP, Dirnhofer S (2011) Frequency, phenotype, and genotype of minute gastrointestinal stromal tumors in the stomach: an autopsy study. Hum Pathol 42: 1849\u20131854.","journal-title":"Hum Pathol"},{"key":"BFbjc2017290_CR25","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/den.12149","volume":"25","author":"T Nishida","year":"2013","unstructured":"Nishida T, Kawai N, Yamaguchi S, Nishida Y (2013) Submucosal tumors: comprehensive guide for the diagnosis and therapy of gastrointestinal submucosal tumors. Dig Endosc 25: 479\u2013489.","journal-title":"Dig Endosc"},{"key":"BFbjc2017290_CR26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10147-008-0822-y","volume":"14","author":"T Nishida","year":"2009","unstructured":"Nishida T, Takahashi T, Nishitani A, Doi T, Shirao K, Komatsu Y, Nakajima K, Hirota S Japanese Study Group on GIST (2009) Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene. Int J Clin Oncol 14: 143\u2013149.","journal-title":"Int J Clin Oncol"},{"key":"BFbjc2017290_CR27","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1185\/03007995.2015.1045470","volume":"31","author":"AP Pilotte","year":"2015","unstructured":"Pilotte AP (2015) Current management of patients with gastrointestinal stromal tumor receiving the multitargeted tyrosine kinase inhibitor sunitinib. Curr Med Res Opin 31: 1363\u20131376.","journal-title":"Curr Med Res Opin"},{"key":"BFbjc2017290_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2217\/fon.14.208","volume":"11","author":"C Porta","year":"2015","unstructured":"Porta C, Giglione P, Liguigli W, Paglino C (2015) Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity. Fut Oncol 11: 39\u201350.","journal-title":"Fut Oncol"},{"key":"BFbjc2017290_CR29","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1158\/1078-0432.CCR-07-1466","volume":"14","author":"D Sarker","year":"2008","unstructured":"Sarker D, Molife R, Evans TR, Hardie M, Marriott C, Butzberger-Zimmerli P, Morrison R, Fox JA, Heise C, Louie S, Aziz N, Garzon F, Michelson G, Judson IR, Jadayel D, Braendle E, de Bono JS (2008) A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res 14: 2075\u20132081.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2017290_CR30","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/j.1572-0241.2005.40709.x","volume":"100","author":"T Tran","year":"2005","unstructured":"Tran T, Davila JA, El-Serag HB (2005) The epidemiology of malignant Gastrointestinal Stromal Tumors: an analysis of 1458 cases from 1992 to 2000. Am J Gastroenterol 100: 162\u2013168.","journal-title":"Am J Gastroenterol"},{"key":"BFbjc2017290_CR31","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1182\/blood-2004-10-3913","volume":"105","author":"S Trudel","year":"2005","unstructured":"Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C, Reece D, Heise C, Stewart AK (2005) CHIR-258, a novel multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 105: 2941\u20132948.","journal-title":"Blood"},{"key":"BFbjc2017290_CR32","doi-asserted-by":"publisher","first-page":"5795","DOI":"10.1200\/JCO.2005.11.601","volume":"23","author":"M Van Glabbeke","year":"2005","unstructured":"Van Glabbeke M, Verweij J, Casali PG, Le Cesne A, Hohenberger P, Ray-Coquard I, Schlemmer M, van Oosterom AT, Goldstein D, Sciot R, Hogendoorn PC, Brown M, Bertulli R, Judson IR (2005) Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 23: 5795\u20135804.","journal-title":"J Clin Oncol"},{"key":"BFbjc2017290_CR33","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1158\/1078-0432.CCR-05-1211","volume":"12","author":"E Wardelmann","year":"2006","unstructured":"Wardelmann E, Merkelbach-Bruse S, Pauls K, Thomas N, Schildhaus HU, Heinicke T, Speidel N, Pietsch T, Buettner R, Pink D, Reichardt P, Hohenberger P (2006) Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 12: 1743\u20131749.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2017290_CR34","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1007\/s10637-013-9961-8","volume":"31","author":"C Yoo","year":"2013","unstructured":"Yoo C, Ryu MH, Tyoo BY, Beck MY, Kang YK (2013) Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg\/day in patients with advanced gastrointestinal stromal tumors. Invest New Drugs 31: 1367\u20131374.","journal-title":"Invest New Drugs"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2017290.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2017290","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/bjc.2017.290","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2017290.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:39:13Z","timestamp":1684417153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2017290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,29]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["BFbjc2017290"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2017.290","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,29]]},"assertion":[{"value":"7 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HJ receives honoraria for consultancy with Blueprint Medicines, Ariad Pharmaceuticals, and Orion Pharma. J-YB reports grants and personal fees from Novartis, grants and personal fees from Bayer, grants and personal fees from Roche, and grants and personal fees from Pfizer, outside the submitted work. AC has nothing to disclose. JM-B serves on the advisory board of Novartis, outside of the submitted work. EF has nothing to disclose. GG reports personal fees from Bayer, personal fees from Novartis, and personal fees from Pfizer, outside the submitted work. XGDM reports advisory role and receiving funding for research from Pfizer and Bayer. AA reports personal fees from Novartis, outside the submitted work. CV reports personal fees from Novartis, personal fees from Bayer, personal fees from Lilly, and personal fees from Pfizer, outside the submitted work. ALP has nothing to disclose. OB reports grants from Novartis, during the conduct of the study; personal fees from Novartis, personal fees from Roche, personal fees from Merck, personal fees from Lilly, and personal fees from Hospira, outside the submitted work. AI has nothing to disclose. SB reports grants and other from Novartis, grants from Blueprint Medicine, grants from Ariad, other from Bayer, other from Pfizer, other from Lilly, during the conduct of the study. CB reports grants from Novartis, outside the submitted work. CW, SC, MC, and RC are Novartis employees. ALC reports personal fees from Pfizer, personal fees from Pharmamar, personal fees from Amgen, personal fees from Lilly, and personal fees from Novartis-GSK, outside the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}